Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 2Phase 2 2Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Glioblastoma 5Neoplasms 3Recurrence 1Neuroectodermal Tumors 1Medulloblastoma 1Brain Neoplasms 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × Lomustine × Clear all
NCT03382977 2026-05-08

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

VBI Vaccines Inc.

Phase 1/2 Terminated
70 enrolled
CNS

Glioblastoma, Neoplasms

NCT02765165 2021-07-23

Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)

Proximagen, LLC

Phase 1/2 Terminated
26 enrolled 20 charts
CNS

Brain Neoplasms, Glioblastoma, Neoplasms, Recurrence

NCT01614132 2020-03-31

NOA-07

University of Regensburg

Phase 1/2 Completed
33 enrolled
CNS

Medulloblastoma, Neoplasms, Neuroectodermal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡